Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ultragenyx Pharma (RARE) Misses Q1 EPS by 8c
May 6, 2019 5:03 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.82), $0.08 worse than the analyst estimate of ($1.74). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $18.3 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More